SUPN
Supernus Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website upernus.com
- Employees(FY) 612
- ISIN US8684591089
Performance
-3.0%
1W
-1.12%
1M
+2.39%
3M
+4.38%
6M
+0.55%
YTD
-17.31%
1Y
Profile
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Investment Analysis Report: Supernus Pharmaceuticals Inc. (SUPN)
Overview
Supernus Pharmaceuticals Inc. (SUPN) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $1.55 billion. In this report, we will conduct a comprehensive analysis of SUPN's financial health...
Technical Analysis of SUPN 2024-05-10
Overview:
In analyzing the technical indicators for SUPN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the m...
Recent News & Updates
- 2024-05-10 13:38
- 2024-05-10 07:03
- 2024-05-09 16:05
- 2024-05-09 11:56
- 2024-05-09 04:05
- 2024-05-09 03:42
- 2024-05-08 23:56
- 2024-05-08 19:00
- 2024-05-08 16:05
Supernus Announces First Quarter 2024 Financial Results(GlobeNewswire)
- 2024-05-08 10:56
- 2024-05-08 04:05
Supernus Announces First Quarter 2024 Financial Results(Globenewswire)
- 2024-05-07 11:46
- 2024-05-07 10:00
- 2024-05-07 09:15
- 2024-05-06 22:00
- 2024-05-06 21:15
- 2024-05-01 08:00
- 2024-04-30 20:00
- 2024-04-24 16:05
- 2024-04-24 04:05
- 2024-04-23 20:00
SUPN: What does Argus have to say about SUPN?(Argus Research)
- 2024-04-08 12:11
- 2024-04-08 08:00
Supernus Provides Regulatory Update for SPN-830(GlobeNewswire)
- 2024-04-07 20:00
Supernus Provides Regulatory Update for SPN-830(Globenewswire)
- 2024-03-27 04:37
Corporate Insiders Are Selling These 10 Small-Cap Stocks(Insidermonkey)
- 2024-03-06 16:30
Supernus to Participate in Two Upcoming Investor Conferences(GlobeNewswire)
- 2024-03-06 03:30
Supernus to Participate in Two Upcoming Investor Conferences(Globenewswire)
- 2024-03-04 20:28
11 Best Small Cap Pharma Stocks to Invest In(Insider Monkey)
- 2024-03-04 07:28
11 Best Small Cap Pharma Stocks to Invest In(Insidermonkey)
- 2024-02-29 06:39
Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
Page 1 of 6
previousnext